Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-06-28

Clinical Trial Update: Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

View source ↗

Summary

A real-life study evaluating the biosimilar Nivestim® for preventing chemotherapy-induced neutropenia; the trial has been terminated with results posted in 2019…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nivestim (filgrastim)

Snippet

Sponsor: Pfizer | Conditions: Chemotherapy-Induced Neutropenia | Status: TERMINATED | Results posted: 2019-06-28